A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

Table 5 Total costs, QALYs and incremental cost-effectiveness estimated in the economic model by patient population

Population	Cost per patient		QALYs per patient		Incremental cost per QALY gained
	ATX arm	Comparator arm	ATX arm	Comparator arm
Population 1 ^a (comparator: IR-MPH)	€ 1 047	€ 366	0.930	0.910	€ 34 308
Population 1 ^a (comparator: XR-MPH)	€ 1 208	€ 902	0.933	0.920	€ 24 310
Population 2 ^b (comparator: 'no medication')	€ 919	€ 0	0.919	0.880	€ 23 820
Population 3 ^c (comparator: 'no medication')	€ 969	€ 0	0.922	0.880	€ 23 323

Abbreviations: ATX = atomoxetine; IR-MPH = immediate-release methylphenidate; XR-MPH = extended-release methylphenidate; QALY = Quality-adjusted life year
a. Stimulant-naïve patients without contra-indications to stimulants
b. Stimulant-failed patients without contra-indications to stimulants
c. Stimulant-naïve patients with contra-indications to stimulants

ISSN: 1471-244X